Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by J.D. Cardenas
P1.04-29 Second or Third Line Nivolumab Versus First Line Nivolumab in Patients With Previously Treated Advanced Non Small Cell Lung Cancer (NSCLC)
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Related publications
Third-Line Nivolumab Monotherapy in Recurrent Small Cell Lung Cancer: CheckMate 032
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
179P: Nivolumab Monotherapy in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice in a Spanish Center
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Pharmacoeconomic Study of Pembrolizumab and Nivolumab in the Second Line of Therapy of Advanced Non-Small Cell Lung Cancer
Effective Pharmacotherapy
P1.04-35 Quick Progression (QP) in Patients Treated by Nivolumab (IO) in 2nd Line or More for Non-Small Cell Lung Cancer: ERORECI Study (GFPC 2016-04)
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Treatment Paradigms for Patients With Metastatic Non-Small-Cell Lung Cancer: First-, Second-, and Third-Line
Current Oncology
Oncology
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab
JAMA Oncology
Cancer Research
Oncology
Cost-Effectiveness of First-Line Therapy for Advanced Non-Small Cell Lung Cancer (Nsclc)
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Predictive Role of Plasmatic Biomarkers in Advanced Non-Small Cell Lung Cancer Treated by Nivolumab
OncoImmunology
Oncology
Allergy
Immunology
Nivolumab in Metastatic Non–Small Cell Lung Cancer
Journal of the Advanced Practitioner in Oncology
